EP2136840A2 - Verwendung eines anti-cxcr4-antikörpers zur krebsbehandlung - Google Patents

Verwendung eines anti-cxcr4-antikörpers zur krebsbehandlung

Info

Publication number
EP2136840A2
EP2136840A2 EP08787975A EP08787975A EP2136840A2 EP 2136840 A2 EP2136840 A2 EP 2136840A2 EP 08787975 A EP08787975 A EP 08787975A EP 08787975 A EP08787975 A EP 08787975A EP 2136840 A2 EP2136840 A2 EP 2136840A2
Authority
EP
European Patent Office
Prior art keywords
antibody
monoclonal antibody
cancer
tumor
cxcr4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08787975A
Other languages
English (en)
French (fr)
Inventor
Christine Klinguer-Hamour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of EP2136840A2 publication Critical patent/EP2136840A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • the present invention relates to a new use of anti-CXCR4 antibodies capable of inhibiting tumor growth, said antibodies being in particular monoclonal of murine, chimeric and humanized origin.
  • the subject of the invention is the use of these antibodies, or of their functional fragments, as a medicament for the prophylactic and / or therapeutic treatment of cancers.
  • the invention finally comprises products and / or compositions comprising such antibodies in combination, for example, with antibodies and / or anticancer agents or conjugated with toxins and their use for the prevention and / or treatment of certain cancers. .
  • the CXCR4 receptor is a G protein-coupled membrane receptor of the chemokine receptor family. There are two isoforms of the CXCR4 receptor composed respectively of 352 and
  • the residue AsnI 1 is glycosylated, the residue Tyr 2 1 is modified by the addition of a sulfate group and there is a disulphide bridge between Cys 109 and 186 on the extracellular portion of the receptor.
  • This receptor is expressed by a number of healthy tissues including endothelial cells, lymphocytes, macrophages, dendritic cells, "natural killers” and weakly in the heart, colon, liver, kidneys and brain.
  • the CXCR4 receptor is over-expressed in a large number of cancers including colon, breast, prostate, lung (small cell and non-small cell), ovarian, pancreatic, kidney, brain and certain lymphomas.
  • the expression of CXCR4 is increased on the metastatic cells versus cancer cells from the primary tumor.
  • SDF-I Stromal-Derived Factor-1
  • CXCL 12 The only known ligand of this receptor is "Stromal-Derived Factor-1 (SDF-I)" or CXCL 12. This is secreted in large quantities by lymph node, bone marrow, liver, lungs and in small amounts in the kidneys, brain and skin.
  • the CXCR4 / SDF-1 axis plays an important role in cancer because it is directly involved in cell migration phenomena and the formation of metastases. Indeed, the cancer cells express the CXCR4 receptor, they migrate and enter the bloodstream. They stop at organs producing large amounts of SDF-I, they multiply and form metastases (Murphy PM., 2001).
  • CXCR4 / SDF-1 axis plays a role in angiogenesis. More specifically, it has been clearly demonstrated in vitro that the CXCR4 receptor and its ligand SDF-I promote angiogenesis by stimulating the expression of VEGF-A which in turn increases the expression of CXCR4 / SDF-1 (Bachelder RE et al., 2002).
  • tumor-associated macrophages are key components of inflammatory circuits for tumor growth.
  • Chemokines including SDF-I, participate in the recruitment of macrophages in tumors.
  • Monoclonal antibodies capable of recognizing the CXCR4 receptor could also reduce the recruitment of macrophages within tumors thereby limiting their effect on tumor growth.
  • the present invention is directed to the use of an antibody, or a functional fragment thereof, capable of binding specifically to the CXCR4 protein for the treatment of cancer.
  • the functional fragments of antibodies according to the invention consist, for example, of fragments Fv, scFv (se for simple chain), Fab, F (ab ') 2 , Fab', scFv-Fc or diabodies, or any fragment of which the half-life time would have been increased by chemical modification, such as the addition of poly (alkylene) glycol such as poly (ethylene) glycol (“PEGylation") (PEGylated fragments called Fv-PEG, scFv-PEG, Fab- PEG, F (ab ') 2 -PEG or Fab'-PEG) ("PEG” according to the English nomenclature Poly (Ethylene) Glycol), or by incorporation into a liposome, microspheres or PLGA, said fragments being capable of generally exercising even a partial activity of the antibody from which they are derived.
  • poly (alkylene) glycol such as poly (ethylene) glycol (“PEGylation")
  • said functional fragments will comprise or comprise a partial sequence of the heavy or light variable chain of the antibody from which they are derived, said partial sequence being sufficient to retain the same binding specificity as the antibody from which it is derived and sufficient affinity, preferably at least equal to 1/100, more preferably at least 1/10 that of the antibody from which it is derived.
  • Such a functional fragment will comprise at least 5 amino acids, preferably 10, 15, 25, 50 and 100 consecutive amino acids of the sequence of the antibody from which it is derived.
  • these functional fragments will be fragments of the Fv, scFv type,
  • antibody fragments of the invention can be obtained from antibodies as previously described by methods such as digestion with enzymes, such as pepsin or papain and / or by cleavage of disulfide bridges. by chemical reduction.
  • the antibody fragments included in the present invention may be obtained by genetic recombination techniques well known to those skilled in the art or by peptide synthesis using, for example, automatic peptide synthesizers such as than those provided by Applied.
  • the antibody used is a murine monoclonal antibody.
  • Antibodies according to the present invention also include chimeric or humanized antibodies.
  • chimeric antibody an antibody which contains a naturally occurring variable (light chain and heavy chain) derived from an antibody of a given species in association with the light chain and heavy chain constant regions of an antibody of a heterologous species to said given species.
  • the antibodies or their chimeric-like fragments used according to the invention can be prepared using genetic recombination techniques.
  • the chimeric antibody can be made by cloning a recombinant DNA comprising a promoter and a sequence coding for the variable region of an antibody non-human monoclonal, particularly murine, according to the invention and a sequence coding for the constant region of human antibody.
  • a chimeric antibody of the invention encoded by such a recombinant gene will for example be a mouse-human chimera, the specificity of this antibody being determined by the variable region derived from murine DNA and its isotype determined by the constant region derived from the murine DNA. Human DNA.
  • Verhoeyn et al. BioEssays, 8:74, 1988.
  • humanized antibody an antibody which contains CDRs regions derived from an antibody of non-human origin, the other parts of the antibody molecule being derived from one (or more) human antibodies.
  • some of the skeletal segment residues (referred to as FR) can be modified to maintain binding affinity (Jones et al., Nature, 321: 522-525, 1986, Verhoeyen et al., Science, 239: 1534 1536, 1988, Riechmann et al., Nature, 332: 323-327, 1988).
  • Humanized antibodies or their functional fragments can be prepared by techniques known to those skilled in the art (such as those described in Singer et al., J. Immun., 150: 2844-2857, 1992; al., Biotechnol Genet Eng.Rev., 10: 1-142, 1992 or Bebbington et al., Bio / Technology, 10: 169-175, 1992). Such humanized antibodies are preferred for use in prophylactic and / or therapeutic treatment methods in vivo. Other humanization techniques are also known to those skilled in the art, for example the "CDR Grafting" technique described by PDL which is the subject of patents EP 0 451 261, EP 0 682 040 and EP 0 939.
  • the present invention is innovative in that, for the first time and contrary to the prejudices of those skilled in the art, it describes and claims the use of an anti-CXCR4 monoclonal antibody capable of acting not only at level of metastases but especially to act directly at the level of tumor growth of primary tumors.
  • the present invention relates to the use of a monoclonal antibody, or a functional fragment thereof, capable of binding specifically to the CXCR4 protein to inhibit tumor growth in vitro and / or in vivo.
  • a primary tumor Tumor cell transformation results in particular in a cell cycle control loss, insensitivity to apoptosis of abnormal repair I 1 DNA. Cancers are then classified according to the type of cell in which the first transformation occurred (lymphomas, carcinomas, sarcomas); this first malignant cell having then divided, forming the primary tumor. Some primary tumors may progress to a more general invasion of the body by escape of tumor cells from this primary tumor: this is called metastasis.
  • primary tumor represents the first stage of cancer development whereas metastases represent a different and subsequent stage towards which primary tumors can evolve.
  • the present invention therefore provides an alternative to existing treatments in that it provides early treatment of primary tumors before the latter metastasize.
  • tumor growth of a primary tumor, it is necessary to understand the increase in the volume of said primary tumor, this increase in volume resulting from different mechanisms, namely vascularization, apoptosis or cell proliferation.
  • vascularization it is necessary to understand the increase of the vascularization at the level of the primary tumor by angiogenesis and / or by vasculogenesis.
  • Angiogenesis consists of the formation of new vessels (neovascularization) originating from a pre-existing capillary network by proliferation and migration of endothelial cells, especially during healing or the development of a cancerous tumor.
  • Vasculogenesis is a process by which endothelial cells and a primitive plexus are generated by differentiation of endothelial cell precursors (angioblasts and hemangioblasts).
  • apoptosis is meant the process by which cells trigger self-destruction in response to a signal. It is a genetically programmed cell death.
  • cell proliferation is meant any process involved in increasing the number of cells. These processes are more about cell division as part of the cell cycle. More specifically, cell proliferation is the uncontrolled and excessive division of cells that gives rise to a tumor.
  • the present invention therefore describes the use of a monoclonal antibody as described above, or one of its functional fragments, capable of inhibiting vascularization, that is to say angiogenesis and / or vasculogenesis , within the primary tumor.
  • the present invention describes the use of an antibody as described above, or one of its functional fragments, capable of inhibiting the cellular proliferation of the tumor cells constituting the primary tumor.
  • the present invention describes the use of an antibody as described above, or one of its functional fragments, capable of inhibiting the vascularization within the primary tumor and the cellular proliferation of tumor cells. constituting said primary tumor.
  • the present invention describes the use of an antibody as described above, or one of its functional fragments, which is also capable of inducing the apoptosis of the tumor cells constituting the primary tumor. .
  • the invention consists mainly in the use of at least one anti-CXCR4 antibody, or one of its functional fragments, which consists of a monoclonal antibody.
  • a monoclonal antibody means an antibody derived from a substantially homogeneous antibody population. More particularly, the individual antibodies of a population are identical with the exception of a few possible mutations that can occur naturally which can be found in minute proportions.
  • a monoclonal antibody consists of a homogeneous antibody resulting from the proliferation of a single cell clone (for example a hybridoma, a eukaryotic host cell transfected with a DNA molecule encoding the homogeneous antibody, a cell prokaryotic host transfected with a DNA molecule encoding the homomgene antibody, etc.) and which is generally characterized by heavy chains of one and the same class and subclass, and light chains of one type.
  • the monoclonal antibodies are highly specific and are directed against a single antigen.
  • each monoclonal antibody is directed against a single epitope of the antigen.
  • the monoclonal antibody used is chosen from antibodies MAB 170 (from clone 12G5), MAB 171 from clone 44708), MAB 172 (from clone 44716) and MAB 173 ( from clone 44717) (http://www.rndsystems.com).
  • each antibody may be named by name or by the name of the hybridoma from which it is derived.
  • the MAB 173 antibody may be indifferently named, especially in the examples, 44717 or MAB 173 or Mabl73.
  • Table 1 summarizes, in a non-exhaustive manner, for each clone, the antibodies available to those skilled in the art from R & D Systems.
  • the monoclonal antibody according to the invention consists of the antibody MAB 173.
  • the present invention therefore describes the use of an anti-CXCR4 monoclonal antibody, or a functional fragment thereof, said monoclonal antibody consisting of the MAB 173.
  • the monoclonal antibody MAB173 was produced from a hybridoma resulting from fusion of murine myeloma with isolated B cells of a mouse immunized with murine 3T3 cells transfected with the hCXCR4 protein. The IgGs were then purified from the ascites fluid by protein G affinity chromatography (R & D Systems Factsheet for MAB 173). This antibody is described as specifically recognizing the human protein
  • an antibody as described above for the preparation of a medicament for the treatment and / or prevention of cancer.
  • anti-CXCR4 antibodies in the context of the treatment and / or prevention of cancer is particularly justified in cancers overexpressing the same CXCR4 receptor.
  • Such cancers consist of cancers of the colon, breast, prostate, lung (small cell and non-small cell), ovarian, pancreas, kidney, brain and some lymphomas.
  • the present invention therefore claims the use of an antibody as described above for the treatment of cancer, said cancer being selected from cancer of the colon, breast, prostate, lung (small cell and non-small cell), ovarian, pancreatic, kidney, brain and some lymphoma.
  • the invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising as active principle a compound consisting of an antibody, or one of its derivative compounds or functional fragments, preferably supplemented with an excipient and / or a pharmaceutically acceptable vehicle.
  • the invention relates to the use of an antibody according to the invention for the preparation of a pharmaceutical composition
  • a pharmaceutical composition comprising, in addition, at least one pharmaceutically acceptable carrier
  • pharmaceutically acceptable carrier is intended to mean a compound or a combination of compounds entering into a pharmaceutical composition that does not cause side reactions and that makes it possible, for example, to facilitate the administration of the active compound (s), to increase its shelf life and / or its effectiveness in the organism, the increase of its solubility in solution or the improvement of its conservation.
  • pharmaceutically acceptable vehicles are well known and will be adapted by those skilled in the art depending on the nature and mode of administration of the selected active compound (s).
  • these compounds will be administered systemically, in particular intravenously, intramuscularly, intradermally, intraperitoneally or subcutaneously, or orally. More preferably, the composition comprising the antibodies according to the invention will be administered several times, spread over time.
  • dosages and optimal dosage forms can be determined according to the criteria generally taken into account in the establishment of a treatment adapted to a patient such as the age or the body weight of the patient, the severity of his general condition, tolerance to treatment and side effects noted.
  • compositions for the treatment of cancer characterized in that it comprises as active ingredient at least one anti-CXCR4 antibody, or one of its functional fragments, capable of binding to CXCR4 protein.
  • compositions comprising at least one anti-CXCR4 antibody, or one of its functional fragments, said at least one antibody being a monoclonal antibody selected from the MAB 170, MAB171 antibodies, MAB172 or MAB173, preferentially the MAB173 antibody.
  • composition which comprises a combination of the above-mentioned antibodies, or functional fragments thereof.
  • the invention also relates to the use of a composition comprising at least one antibody as described above for the treatment of cancer of the colon, breast, prostate, lung (small cell and not small cells), ovary, pancreas, kidney, brain and some lymphomas.
  • Another complementary embodiment of the invention consists of a composition as described above, characterized in that it comprises, in addition, as a combination product for simultaneous, separate or spread use over time, at least a cytotoxic / cytostatic agent and / or a cellular toxin and / or a radioelement.
  • cytotoxic / cytostatic agent and / or a cellular toxin and / or a radioelement.
  • disparate use is meant the administration, at the same time, of the two compounds of the composition according to the invention, included in different pharmaceutical forms.
  • use spread over time the successive administration of the two compounds of the composition according to the invention, each included in a separate pharmaceutical form.
  • the composition according to the invention considerably increases the effectiveness of cancer treatment.
  • the therapeutic effect of the antibody according to the invention is unexpectedly potentiated by the administration of a cytotoxic agent.
  • Another major subsequent advantage produced by a composition according to the invention concerns the possibility of using lower effective doses of active ingredient, which makes it possible to avoid or reduce the risks of occurrence of side effects, in particular the effect of the cytotoxic agent.
  • this composition according to the invention would make it possible to achieve the desired therapeutic effect more rapidly.
  • Anti-cancer therapeutics or "cytotoxic agents” means a substance that, when administered to a patient, treats or prevents the development of cancer in the patient.
  • agents alkylating agents, antimetabolites, anti-tumor antibiotics, mitotic inhibitors, chromatin function inhibitors, anti-angiogenesis agents, anti-estrogens, anti-androgens or immunois- modulators.
  • agents are, for example, cited in VIDAL, on the page dedicated to the compounds attached to oncology and hematology column "Cytotoxic", these cytotoxic compounds cited with reference to this document are cited here as preferred cytotoxic agents.
  • Alkylating agents refers to any substance that can covalently couple or alkylate any molecule, preferentially a nucleic acid (eg, DNA), within a cell.
  • nitrogen mustards such as mechlorethamine, chlorambucil, melphalan, hydrochloride, pipobroman, prednimustine, disodium phosphate or estramustine; oxazaphosphorines such as cyclophosphamide, altretamine, trofosfamide, sulfofosfamide or ifosfamide; aziridines or ethylenimines such as thiotepa, triethyleneamine or altetramine; nitrosoureas such as carmustine, streptozocin, fotemustine or lomustine; alkyl sulfonates such as busulfan, treosulfan or improvosulfan; triazenes such as
  • Antimetabolites refers to substances that block growth and / or cell metabolism by interfering with certain activities, usually DNA synthesis.
  • antimetabolite mention may be made of methotrexate, 5-fluorouracil, floxuridine, 5-fluorodeoxyuridine, capecitabine, cytarabine, fludarabine, cytosine arabinoside, 6-mercaptopurine (6-MP), 6-thioguanine (6- TG), chlorodeoxyadenosine, 5-azacytidine, gemcitabine, cladribine, deoxycoformycin and pentostatin.
  • Anti-tumor antibiotics refers to compounds that can prevent or inhibit the synthesis of DNA, RNA and / or proteins.
  • anti-tumor antibiotics include doxorubicin, daunorubicin, idarubicin valrubicin, mitoxantrone, dactinomycin, mithramycin, plicamycin, mitomycin C, bleomycin, and procarbazine.
  • Mitotic inhibitors prevent normal progression of the cell cycle and mitosis.
  • inhibitors of microtubules or “taxoids” paclitaxel and docetaxel are able to inhibit mitosis.
  • Vinca alkaloids such as vinblsatin, vincristine, vindesine and vinorelbine are also able to inhibit mitosis.
  • Chroisomerase inhibitors refer to substances that inhibit the normal function of chromatin-forming proteins such as topoisomerases I and II. Examples of such inhibitors include, for topoisomerase I, camptothecin and its derivatives such as Firinotecan or topotecan and, for topoisomerase II, etoposide, etidoside phosphate and teniposide.
  • Anti-angiogenesis agents refer to any drug, compound, substance or agent that inhibits the growth of blood vessels.
  • anti-angiogenesis agents include, without limitation, razoxin, marimastat, batimastat, prinomastat, tanomastat, ilomastat, CGS-27023A, halofuginone, COL-3, neovastat, BMS-275291, thalidomide, CDC 501, DMXAA, L-651582, squalamine, endostatin, SU5416, SU6668, interferon-alpha, EMD121974, interleukin-12, IM862, angiostatin and vitaxine.
  • Anti-estrogen or “anti-estrogenic agents” refers to any substance that decreases, antagonizes or inhibits the action of estrogen. Examples of such agents are tamoxifen, toremifene, raloxifene, droloxifene, iodoxyfen, anastrozole, letrozole, and exemestane.
  • Anti-androgens or “anti-androgenic agents” refer to any substance that reduces, antagonizes or inhibits the action of an androgen.
  • antiandrogens are flutamide, nilutamide, bicalutamide, sprironolactone, cyproterone acetate, finasteride and cimitidine.
  • Immunomodulators are substances that stimulate the immune system.
  • immunomodulators examples include interferons, interleukins such as aldesleukin, OCT-43, denileukin diflitox or interleukin-2, tumor necrosis factors such as tasonermin, or other types of immunomodulators such as lentinan, sizofiran, roquinimex, pidotimod, pegademase, thymopentine, poly I: C, or levamisole in combination with 5-fluorouracil.
  • interferons such as aldesleukin, OCT-43, denileukin diflitox or interleukin-2
  • tumor necrosis factors such as tasonermin
  • immunomodulators such as lentinan, sizofiran, roquinimex, pidotimod, pegademase, thymopentine, poly I: C, or levamisole in combination with 5-fluorouracil.
  • said composition as a combination product according to the invention is characterized in that said cytotoxic agent is chemically coupled to said antibody for simultaneous use.
  • said composition according to the invention is characterized in that said cytotoxic / cytostatic agent is chosen from inhibitors or spindle stabilizers, preferably vinorelbine and / or vinflunine and / or vincristine.
  • said cytotoxic agent is chosen from inhibitors or spindle stabilizers, preferably vinorelbine and / or vinflunine and / or vincristine.
  • spacer molecules between the two compounds to be coupled such as poly (alkylenes) glycols such as polyethylene glycol, or else amino acids, or in another embodiment, using active derivatives of said cytotoxic agents in which have been introduced functions capable of reacting with said antibody according to the invention.
  • the invention is, in another aspect, relating to a composition characterized in that at least one of said antibodies, or one of their derivative compound or functional fragment, is conjugated with a cellular toxin and / or a radioissement
  • said toxin or said radioelement is capable of preventing growth or proliferation of the tumor cell, in particular completely inactivating said tumor cell.
  • said toxin is an enterobacterial toxin, especially exotoxin A of Pseudomonas.
  • the radioelements preferably conjugated to the antibody used in therapy are radioisotopes that emit gamma rays and preferably iodine 131 , yttrium 90 , gold 199 , palladium 100 , copper 67 , bismuth 217 and Fantimony 211 . Radioisotopes that emit beta and alpha rays can also be used in therapy.
  • toxin or radioelement conjugated to at least one antibody, or one of their functional fragment is meant any means for binding said toxin or said radioelement to said at least one antibody, in particular by covalent coupling between the two compounds, with or without the introduction of a binding molecule.
  • benzoquinone carbodiimide and more particularly EDC (1-ethyl-3- [3] may be mentioned in particular.
  • bridging agents having one or more groups, having a or more phenylase groups, reactive with ultraviolet (UV) and most preferably N - [- 4- (azidosalicylamino) butyl] -3 '- (2'-pyridyldithio) propionamide (APDP), N-succinimid-yl 3- (2-pyridyldithio) propionate (SPDP) and 6-hydrazino-nicotinamide (HYNIC).
  • UV ultraviolet
  • APDP N- [- 4- (azidosalicylamino) butyl] -3 '- (2'-pyridyldithio) propionamide
  • SPDP N-succinimid-yl 3- (2-pyridyldithio) propionate
  • HYNIC 6-hydrazino-nicotinamide
  • Another form of coupling may be the use of a bifunctional ion chelator.
  • chelators it is possible to mention the chelates derived from EDTA
  • DTPA diethylenetriaminepentaacetic acid
  • metals particularly radioactive metals, and immunoglobulins.
  • DTPA and its derivatives can be substituted by different groups on the carbon chain so as to increase the stability and rigidity of the ligand-metal complex (Krejcarek et al (1977), Brechbiel et al (1991), Gansow (1991) US Patent 4,831,175).
  • DTPA diethylenetriaminepentaacetic acid
  • its derivatives which has been widely used in medicine and biology for a long time either in its free form or in the form of a complex with a metal ion, has the remarkable characteristic of form stable chelates with metal ions and be coupled to proteins of therapeutic or diagnostic interest as antibodies for the development of radioimmunoconjugates in cancer therapy (Meases et al., (1984), Gansow et al. (1990)).
  • the composition according to the invention further comprises at least one second antibody known for its antitumor activity.
  • the antibodies anti Her2 / neu (Herceptin), anti-EGFR (Erbitux) or anti-IGF-1R (7C10 or h7C10) may be mentioned.
  • any antitumor antibody may be included in the composition according to the invention.
  • the present invention further comprises the use of the composition according to the invention for the preparation of a medicament.
  • the present invention therefore relates more particularly to the use of a composition as described above for the preparation of a medicament for the treatment of cancer.
  • cancers that can be prevented and / or treated, cancer of the colon, breast, prostate, lung (small cells and non-small cells), ovary, pancreas, kidney, brain and certain lymphomas.
  • the subject of the invention is also the use of an antibody according to the invention for the preparation of a medicinal product intended for the specific targeting of a biologically active compound to cells expressing or overexpressing the CXCR4 receptor.
  • biologically active compound is intended to mean any compound capable of modulating, in particular of inhibiting, cell activity, in particular their growth, proliferation, transcription or gene translation.
  • Figure 1 illustrates the study of the inhibition by SDF1 and the 44717 antibody of [ 125 I] SDF1 binding on CHO-K1 cell membranes constitutively expressing the human CXCR4 receptor.
  • Figure 2 illustrates the study of [ 35 S] GTP ⁇ S binding to CHO-K1 cell membranes constitutively expressing the human CXCR4 receptor: influence of SDF 1 and antibody 44717.
  • Figure 3 illustrates the study of intracellular calcium release on intact CHO-K1 cells expressing the CXCR4 receptor: influence of SDF1 and antibody 44717.
  • Figure 4 shows the in vivo antitumour activity of monoclonal antibody 44717 in the U-937 xenograft model.
  • Figure 5 shows the inhibition of tumor growth in the MDA-MB-231 xenograft model by monoclonal antibody 44717.
  • Example 1 Inhibition test of the binding of [ 125 IlSDF-I by antibody 44717 (otherwise known as MAB173)
  • CHO-K1 cells constitutively expressing the human CXCR4 receptor are obtained by stable transfection with an expression vector containing the entire coding sequence of human CXCR4. These cells are cultured in DMEM-Ham's F 12 complete culture medium containing 5% fetal calf serum (FCS) and 500 ⁇ g / ml geneticin. The binding assays are performed on cell membranes obtained after mechanically scraping the cells in [Hepes 20mM, pH 7.4, 15mM NaCl] buffer and harvested by centrifugation at 10000g, 15 min.
  • FCS fetal calf serum
  • the binding of [ 125 I] SDF1 (specific activity 1500 Ci / mmol) is measured in homogeneous medium using SPA (scintillation proximity assay - GE Healthcare) beads in 96-well plates. Briefly, the membranes (30 ⁇ g / well) are incubated in the binding buffer [Hepes 20 mM, pH 7.4, 1 mM CaCl 2 , 5 mM MgCl 2, 15 mM NaCl, 1% BSA] with the test compound (SDF1 or antibody 44717). the radioligand (InM) and then the SPA-WGA-PVT beads (7.3 mg / well) and incubated at 25 ° C. After centrifugation [10 min. at 1000g] the radioactivity is read in a scintillation counter (TopCount, Perkin Elmer). The nonspecific binding of [ 125 I] SDF1 is determined in the presence of 10 ⁇ M of unlabeled SDF1.
  • SPA sintillation proximity assay -
  • CHO-K1 cells constitutively expressing the human CXCR4 receptor are obtained in the same manner as described in Example 1.
  • the binding assays are carried out on cell membranes obtained after mechanical scraping of the cells in a buffer [Hepes 20 mM, pH 7.4, 15OmM NaCl] and collected by centrifugation 10000g, 15 min.
  • the binding of [ 35 S] GTPyS (specific activity 1000 Ci / mmol) is measured in homogeneous medium using SPA (scintillation proximity assay - GE Healthcare) beads in 96-well plates.
  • SDF1 stimulates in a dose-dependent manner the binding of [ 35 S] GTPyS reflecting the activation of the CXCR4 receptor.
  • This test makes it possible to evaluate the signaling of the CXCR4 receptor by the Phospholipase C pathway, inducing the release of intracellular calcium. This kinetic test makes it possible to follow the evolution of the system over time.
  • CHO-K1 cells constitutively expressing the human CXCR4 receptor are obtained in the same manner as described in Example 1.
  • the cells are seeded in plate 96 black wells [100,000 cells in DMEM-F 12 medium-5% FCS] / well] and weaned on the night.
  • the cells are loaded with a fluorescent calcium probe (Fluo-4 No Wash) in the buffer [HBSS Ix, HEPS 20 ⁇ M, Probenicid acid 25 mM] for 30 min. at 37 0 C then 30 min. at 25 ° C.
  • 10 .mu.l of solution of the antibody 44717 are added to the cells.
  • the measurement is carried out using the Mithras reader LB940 (Berthold) in fluorescence mode with the following parameters: excitation at 485 nm, emission at 535 nm and lamp at an energy of 10000.
  • Each well is read 0.1 seconds, every second over a period of 20 seconds (basal signal) then 20 .mu.l of SDF-I are injected and the well reads again for 2 min.
  • Each experimental condition is tested in duplicate.
  • the results are corrected by subtracting the values of a cell free well to the cell well values.
  • the values are then expressed in% of the base signal and corrected so that the first value after adding SDF-I is 100%. This makes it possible to compensate for the random jump of fluorescence induced by the injection of the ligand
  • SDF1 (300 nM) induces calcium release with CHO / CXCR4 cells, whereas no response is observed on naive CHO-Kl cells.
  • the signal maximum is obtained after about 30 sec and the maximum efficiency of SDF-I is 180% of the basal signal (Fig. 3).
  • Antibody 44717 (133 nM) strongly inhibited the SDF1 -induced calcium release that reached a maximum of 130% basal signal after one minute after SDF1 injection (Fig. 3).
  • Example 4 Anti-tumor activity of the 44717 antibody in the U937 xenograft model in NOD scid mice.
  • the U-937 cells were cultured in RPMI 1640 medium with phenol red and 4.5 g / l of glucose (Sigma, ref G8769), supplemented with 10% FCS (F7524, Sigma) and 2 mM L-Glutamine ( BioWhittaker ref BE17-605E). The cells were seeded two days before the transplant, they were exponential growth phase during implantation in the animal. Ten million U-937P ((2) +4) cells were grafted to 8 week old female Nod / Scid mice by intraperitoneal injection (strain: SOPF / NOD.CB17PRKDC / J FE 6 S, NOD.CB17- Prkdc scid / J, ref NSCSSFE06S, Charles River Laboratories).
  • IgG2b group IgG2b, (Sigma ref M2695, Sigma lot 046K4843, lot 22060307, 3 mg / ml), 1 mg / dose per mouse, twice a week
  • the first dose was 2 mg per mouse for the control IgG2b antibodies and the 44717 antibody.
  • the choice of the sc pathway for the treatment was selected so as to avoid any direct contact between the tumor cells and the antibody in the cavity. peritoneal.
  • the first mouse died after 15 days in the IgG2b group. All but one mouse died within seven days (Fig. 4). The surviving mouse was euthanized 82 days after the transplant and examined, there were no tumor cells in its abdominal cavity.
  • mice began to die within 4-6 days of the other two control groups. Eight mice died between days 22 and 27. Two mice survived until day 109, the day they were euthanized (Fig. 4). A statistical analysis of the survival results (Kaplan-Meier) was performed using the Log-Rank test (Fig. 4). The experiment described here shows that monoclonal antibody 44717 directed against the CXCR4 receptor is capable of increasing mouse survival in the U937 xenograft model.
  • Example 5 Inhibition of tumor growth by the 44717 antibody in the MDA-MB-231 xenograft model in the athmic Nude mouse.
  • MDA-MB-231 cells (ECACC) were cultured in DMEM medium (Invitrogen Corporation, Scotland, UK), in the presence of 10% FCS (Sigma). The cells were inoculated 60 hours before the transplant. They were in an exponential phase of growth during implantation. Ten million MDA-MB-231 cells (P35 + 18) were grafted in PBS to 7 week old Nude Athymic (HARLAN) mice. Five days after implantation, the tumors were measurable (37 mm 3 ⁇ V 3 ⁇ 44 mm 3 ) and the animals were randomly divided into groups of 12 mice with comparable tumor sizes.
  • mice were treated ip with a dose of monoclonal antibody 44717 (lots AUZ05607A and AUZ04512A, R & D Systems) of 2mg / mouse. Then, the mice received, twice a week, a 44717 monoclonal antibody dose of 1 mg / mouse. In this experiment a group of control mice received an equivalent volume of PBS. The volume of the tumors was measured twice a week and calculated using the following formula: ⁇ / 6 X length X width X height.
  • the average tumor volume after 5 weeks of treatment was reduced by 56% for the 44717 antibody relative to the PBS.
  • the experiment described here shows that monoclonal antibody 44717 directed against the CXCR4 receptor is capable of inhibiting tumor growth in a MDA-MB-231 xenograft model in athymic Nude mouse.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP08787975A 2007-04-23 2008-04-18 Verwendung eines anti-cxcr4-antikörpers zur krebsbehandlung Withdrawn EP2136840A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0702977A FR2915102B1 (fr) 2007-04-23 2007-04-23 Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
PCT/FR2008/000553 WO2008142303A2 (fr) 2007-04-23 2008-04-18 Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer

Publications (1)

Publication Number Publication Date
EP2136840A2 true EP2136840A2 (de) 2009-12-30

Family

ID=38448025

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08787975A Withdrawn EP2136840A2 (de) 2007-04-23 2008-04-18 Verwendung eines anti-cxcr4-antikörpers zur krebsbehandlung

Country Status (6)

Country Link
US (1) US20100150935A1 (de)
EP (1) EP2136840A2 (de)
JP (1) JP2010526044A (de)
CA (1) CA2683452A1 (de)
FR (1) FR2915102B1 (de)
WO (1) WO2008142303A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009246683A1 (en) * 2008-05-14 2009-11-19 Eli Lilly And Company Anti-CXCR4 antibodies
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
JP5975886B2 (ja) * 2010-03-11 2016-08-23 ヘルス リサーチ インコーポレイテッドＨｅａｌｔｈ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． Ｆｃ融合タンパク質を含む、免疫応答を増強するための方法および組成物
EP3626739A1 (de) 2011-06-24 2020-03-25 Stephen D. Gillies Leichtkettige immunglobulinfusionsproteine und verfahren zur verwendung davon
ES2705001T3 (es) 2011-11-09 2019-03-21 Bristol Myers Squibb Co Tratamiento de neoplasias hematológicas con un anticuerpo anti-CXCR4
MX2017015811A (es) 2015-06-12 2018-04-10 Squibb Bristol Myers Co Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
WO2017220990A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 antibodies
CN112513079A (zh) 2018-03-13 2021-03-16 拉巴斯大学医院生物医学研究基金会 用于癌症免疫疗法的联合激活和扩增的自然杀伤细胞的抗cxcr4抗体
US20210024873A1 (en) 2018-03-27 2021-01-28 Bristol-Myers Squibb Company Real-time monitoring of protein concentration using ultraviolet signal
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
WO2020237221A1 (en) 2019-05-23 2020-11-26 Bristol-Myers Squibb Company Methods of monitoring cell culture media
US20230374064A1 (en) 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008060367A2 (en) * 2006-10-02 2008-05-22 Medarex, Inc. Human antibodies that bind cxcr4 and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080112950A1 (en) * 2002-11-07 2008-05-15 Lobo Peter I Naturally occurring IgM antibodies that bind lymphocytes
PE20020376A1 (es) * 2000-09-29 2002-05-13 Abbott Lab Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
US20050002939A1 (en) * 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
CA2597717C (en) * 2005-02-18 2014-10-21 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008060367A2 (en) * 2006-10-02 2008-05-22 Medarex, Inc. Human antibodies that bind cxcr4 and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "MDA-MB-231 (ATCC(R) HTB-26TM) Homo sapiens mammary gland/breast", 16 December 2013 (2013-12-16), XP055093634, Retrieved from the Internet <URL:http://www.lgcstandards-atcc.org/products/all/HTB-26.aspx?geo_country=nl#characteristics> [retrieved on 20131216] *
N.N: "The mutation data was obtained from the Sanger Institute Catalogue Of Somatic Mutations", 16 December 2013 (2013-12-16), XP055093650, Retrieved from the Internet <URL:http://www.lgcstandards-atcc.org/~/media/CE379788822442FA8EC05617FDCF9ACD.ashx> [retrieved on 20131216] *

Also Published As

Publication number Publication date
CA2683452A1 (fr) 2008-11-27
FR2915102A1 (fr) 2008-10-24
WO2008142303A3 (fr) 2009-01-22
US20100150935A1 (en) 2010-06-17
FR2915102B1 (fr) 2014-05-16
WO2008142303A2 (fr) 2008-11-27
JP2010526044A (ja) 2010-07-29

Similar Documents

Publication Publication Date Title
EP2136840A2 (de) Verwendung eines anti-cxcr4-antikörpers zur krebsbehandlung
CN107849142B (zh) 拮抗性抗肿瘤坏死因子受体超家族抗体
EP2079482B1 (de) Verwendung eines antikörpers gegen cd151 bei der behandlung von primären krebs
JP2022116283A (ja) 三重特異性タンパク質と使用方法
KR20220085796A (ko) 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
KR101063278B1 (ko) Ｂ-세포 림프종을 치료하기 위한 항-ｃｄ２０ 항체를 포함하는 약제
CN111936164A (zh) 癌的治疗和/或预防用药物组合物
FI3886875T3 (fi) Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
KR20220091576A (ko) 혈액암의 항-cd47 및 항-cd20 기반 치료
FR2906533A1 (fr) Procede de generation d&#39;anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
JP5688734B2 (ja) 移植片対腫瘍効果を保存した免疫学的再構築促進剤または感染症予防剤
FR2909092A1 (fr) Nouveaux anticorps anti-proliferation
CA2720904A1 (fr) Nouveaux anticorps utiles pour le traitement du cancer
CN113474004A (zh) 用于治疗肿瘤的包含抗cd19抗体和自然杀伤细胞的药物组合
JP2021501217A (ja) 同種キメラ抗原受容体ｔ細胞投与のための方法および組成物
Parrondo et al. Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives
JP2023523572A (ja) Ａｔｒａ又はその他のレチノイドと、ｂｃｍａに結合する免疫療法用薬剤との併用療法
EP2262839B1 (de) Verwendung eines antikörpers gegen cd151 zur frühen behandlung von krebs
JP7317343B2 (ja) 乳がんの予防又は治療剤及び乳がん細胞の増殖抑制剤
US20240156863A1 (en) Sequential anti-cd19 therapy
TW200924793A (en) Cancerous disease modifying antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091123

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20120308

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20140225